Clinical Trials Browser

Terminated × INDUSTRY × durvalumab × Clear all

Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Disease Progression

NCT06939036 2026-02-05

SANTANA-225

Phase 1/2 Terminated

2 enrolled

Dermatologic

Carcinoma, Merkel Cell

NCT04613492 2025-06-24

A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors

Phase 1 Terminated

40 enrolled

Other solid neoplasm

Solid Tumors

NCT04870112 2025-04-17

SCope-D1

Phase 1 Terminated

18 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT04866017 2024-10-31

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

Phase 3 Terminated

63 enrolled 15 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03323398 2024-07-31

Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

Phase 1/2 Terminated

79 enrolled 18 charts

GynecologicLymphoid

Lymphoma, Ovarian Neoplasms, Recurrence

NCT03840902 2024-01-16

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Phase 2 Terminated

153 enrolled 13 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03970616 2023-07-12

DEDUCTIVE

Phase 1/2 Terminated

27 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT02291055 2023-03-20

A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer

Phase 1/2 Terminated

75 enrolled 23 charts

GynecologicHead & Neck

Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms

NCT02807454 2023-02-21

FUSIONMM-003

Phase 2 Terminated

37 enrolled 21 charts

Plasma cell

Multiple Myeloma, Recurrence

NCT03665129 2022-01-27

STELLAR-001

Phase 1 Terminated

73 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT03685344 2021-10-26

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Phase 1 Terminated

13 enrolled 15 charts

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02805660 2021-04-06

Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC

Phase 1/2 Terminated

83 enrolled 26 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Phase 1/2 Terminated

7 enrolled

Solid Cancer

NCT02737072 2019-08-12

A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

Phase 1 Terminated

9 enrolled 13 charts

Other solid neoplasm

Solid Tumor

NCT02556463 2018-12-19

A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

Phase 1 Terminated

53 enrolled

Tumor-Agnostic

Neoplasms

NCT02205333 2017-06-28

MEDI6469

Phase 1/2 Terminated

48 enrolled 28 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

Clinical Trials

BOLSTER

SANTANA-225

A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors

SCope-D1

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

DEDUCTIVE

A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer

FUSIONMM-003

STELLAR-001

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

MEDI6469